1. A clinicopathologic analysis of adriamycin cardiotoxicity;Lefrak, E.A.; Pitha, J.; Rosenheim, S.; Gottlieb, J.A.;Cancer,1973
2. Risk factors for doxorubicin-induced congestive heart failure;DD, Von Hoff; MW, Layard; P, Basa;Ann Intern Med,1979
3. Anthracycline cardiomyopathy monitored by morphologic changes;Billingham, M.E.; Mason, J.W.; Bristow, M.R.; Daniels, JR;Cancer Treat Rep,1978
4. New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials;Oki, T.; Takeuchi, T.; Oka, S.; Umezawa, H.;Recent Results Cancer Res,1981
5. Epirubicin: a therapeutically active doxorubicin analogue with reduced cardiotoxicity;Young, C.W.,1984